Insulin devices: Addressing barriers to insulin therapy with the ideal pen

Diabetes Educator

Volumn 34, Issue 6, 2008, Pages 957-967

  Spollett, Geralyn ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ARTICLE; EQUIPMENT DESIGN; HUMAN; INSTRUMENTATION; INSULIN INFUSION; SUBCUTANEOUS DRUG ADMINISTRATION; SYRINGE;

EQUIPMENT DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; SYRINGES;

EID: 57649148778     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721708326763     Document Type: Article

References (38)

1. Dcct. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993 ; 329: 977-986.
2. Ukpds. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet. 1998 ; 352: 837-853.
3. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006 ; 29: 1963-1972.
4. Riddle MC Timely initiation of basal insulin. Am J Med. 2004 ; 116 (supp l3A). 3S - 9S.
5. Cryer P., Childs BP Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum. 2002 ; 15: 20-27.
6. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002 ; 26: S18 - S24.
7. Riddle MC, Rosenstock J., Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003 ; 26: 3080-3086.
8. Raslova K., Bogoev M., Raz I., Leth G., Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004 ; 66: 193-201.
9. Stewart K., Wilson M., Rider J. Insulin delivery devices. J Pharm Pract. 2004 ; 17: 20-28.
10. Klein R., Klein BE, Moss SE Visual impairment in diabetes. Ophthalmology. 1984 ; 91: 1-9.
11. Starkman HS, Gleason RE, Rand LI, Miller DE, Soeldner JS Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: relation to chronic complications. Ann Rheum Dis. 1986 ; 45: 130-135.
12. Ziegler D., Gries FA, Spuler M., Lessmann F. The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. Diabetes Med. 1993 ; 10 (suppl 2). 82S - 86S.
13. Bhatia V., Wolfsdorf JI Severe hypoglycemia in youth with insulin-dependent diabetes mellitus: frequency and causative factors. Pediatrics. 1991 ; 88: 1187-1193.
14. Limbert C., Schwingshandl J., Haas J., Roth R., Borkenstein M. Severe hypoglycemia in children and adolescents with IDDM: frequency and associated factors. J Diabetes Complications. 1993 ; 7: 216-220.
15. Mohn A., Dunger D. Insulin therapy in children and adolescents with type 1 diabetes. Curr Paediatrics. 1999 ; 9: 158-163.
16. Bell DS, Clements RS Jr, Perentesis G., Roddam R., Wagenknecht L. Dosage accuracy of self-mixed vs premixed insulin. Arch Intern Med. 1991 ; 151: 2265-2269.
17. Gnanalingham MG, Newland P., Smith CP Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child. 1998 ; 79: 59-62.
18. Gossain VV, Carella MJ, Rovner DR Management of diabetes in the elderly: a clinical perspective. J Assoc Acad Minor Phys. 1994 ; 5: 22-31.
19. Rosenstock J. Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging. 2001 ; 18: 31-44.
20. Fleming DR Mightier than the syringe. Am J Nurs. 2000 ; 100: 44-48.
21. Kadiri A., Chraibi A., Marouan F., et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract. 1998 ; 41: 15-23.
22. Hanas R., Ludvigsson J. Experience of pain from insulin injections and needle-phobia in young patients with IDDM. Pract Diabetes Int. 1997 ; 14: 95-99.
23. Lteif AN, Schwenk WF Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care. 1999 ; 22: 137-140.
24. Plevin S., Sadur C. Use of a prefilled insulin syringe (Novolin Prefilled) by patients with diabetes. Clin Ther. 1993 ; 15: 423-431.
25. Korytkowski M., Bell D., Jacobsen C., Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003 ; 25: 2836-2848.
26. Corsi A., Torre E., Coronel G., Ghisoni G. Pre-filled insulin pen in newly insulin-treated diabetic patients over 60 years old. Diabetes Nutr Metab. 1997 ; 10: 78-81.
27. Coscelli C., Lostia S., Lunetta M., Nosari I., Coronel GA Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract. 1995 ; 28: 173-177.
28. Shelmet J., Schwartz S., Cappleman J., et al. Preference and resource utilization in elderly patients: InnoLet versus vial/ syringe. Diabetes Res Clin Pract. 2004 ; 63: 27-35.
29. Llewelyn J., Martin J., Bates P. Patient acceptability and safety of a new 3.0 ml pre-filled insulin pen in a clinical setting. Pract Diabetes. 1999 ; 16: 79-81.
30. Hall G. Converting people with type 2 diabetes to insulin in primary care: insulin conversions. 2002. http://findarticles.com/p/articles/mi-m0MDP/is- 1-4/ai-90987563/pg-1. Accessed January 18, 2007.
31. Haak T., Edelman S., Walter C., Lecointre B., Spollett G. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007 ; 29: 650-660.
32. Ristic S., Bates PC, Martin JM, Llewelyn JA Acceptability of a reusable insulin pen, HumaPen Ergo, by patients with type 1 and type 2 diabetes. Curr Med Res Opin. 2002 ; 18: 68-71.
33. Roberts A., Thornley S. Health care professional-reported usability of SoloStar in a 3-month observational survey in everyday clinical practice. J Diabetes Sci Technol. 2007 ; 1 (suppl 1). A151.
34. De Luise M., Beillin J., Morton A., Carter J. Influence of diabetes type and previous experience of pen devices on acceptance and usability of a new pen: an observational survey on SoloStar use. J Diabetes Sci Technol. 2007 ; 1 (suppl 1). A30.
35. Fox C., McKinnon C., Wall A., Lawton S. Ability to handle, and patient preference for, insulin delivery devices in visually impaired patients with type 2 diabetes. Pract Diabetes Int. 2002 ; 19: 104-107.
36. Niskanen L., Jensen LE, Rastam J., Nygaard-Pedersen L., Erichsen K., Vora JP Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004 ; 26: 531-540.
37. Summers KH, Szeinbach SL, Lenox SM Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004 ; 26: 1498-1505.
38. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004 ; 27: 2495-2497.